Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2015 15
2016 1
2017 2
2018 3
2019 8
2020 1
2021 1
2023 3
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. INSIGHT START Study Group, et al. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20. N Engl J Med. 2015. PMID: 26192873 Free PMC article. Clinical Trial.
Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV.
Pelchen-Matthews A, Mocroft A, Ryom L, Ross MJ, Sharma S, Coca S, Achhra A, Cornell E, Tracy R, Phillips A, Alonso MM, Toulomi G, Agan BK, Medland N, Wyatt CM; INSIGHT START Study Group. Pelchen-Matthews A, et al. Kidney Int. 2024 Jul;106(1):136-144. doi: 10.1016/j.kint.2024.04.010. Epub 2024 May 1. Kidney Int. 2024. PMID: 38697479 Free PMC article. Clinical Trial.
Rate of response to initial antiretroviral therapy according to level of pre-existing HIV-1 drug resistance detected by next-generation sequencing in the strategic timing of antiretroviral treatment (START) study.
Cozzi-Lepri A, Dunn D, Tostevin A, Marvig RL, Bennedbaek M, Sharma S, Kozal MJ, Gompels M, Pinto AN, Lundgren J, Baxter JD; INSIGHT START Study Group. Cozzi-Lepri A, et al. HIV Med. 2024 Feb;25(2):212-222. doi: 10.1111/hiv.13556. Epub 2023 Sep 29. HIV Med. 2024. PMID: 37775947
Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection.
Borges ÁH, Neuhaus J, Babiker AG, Henry K, Jain MK, Palfreeman A, Mugyenyi P, Domingo P, Hoffmann C, Read TR, Pujari S, Meulbroek M, Johnson M, Wilkin T, Mitsuyasu R; INSIGHT START Study Group. Borges ÁH, et al. Clin Infect Dis. 2016 Dec 15;63(12):1668-1676. doi: 10.1093/cid/ciw621. Epub 2016 Sep 8. Clin Infect Dis. 2016. PMID: 27609756 Free PMC article. Clinical Trial.
Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.
Baxter JD, Dunn D, Tostevin A, Marvig RL, Bennedbaek M, Cozzi-Lepri A, Sharma S, Kozal MJ, Gompels M, Pinto AN, Lundgren J; INSIGHT START Study Group. Baxter JD, et al. HIV Med. 2021 May;22(5):360-371. doi: 10.1111/hiv.13038. Epub 2020 Dec 25. HIV Med. 2021. PMID: 33369017 Free PMC article.
Deep-sequencing of viral genomes from a large and diverse cohort of treatment-naive HIV-infected persons shows associations between intrahost genetic diversity and viral load.
Gabrielaite M, Bennedbæk M, Rasmussen MS, Kan V, Furrer H, Flisiak R, Losso M, Lundgren JD; INSIGHT START Study Group; Marvig RL. Gabrielaite M, et al. PLoS Comput Biol. 2023 Jan 3;19(1):e1010756. doi: 10.1371/journal.pcbi.1010756. eCollection 2023 Jan. PLoS Comput Biol. 2023. PMID: 36595537 Free PMC article.
ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial.
Sereti I, Gulick RM, Krishnan S, Migueles SA, Palfreeman A, Touzeau-Römer V, Belloso WH, Emery S, Law MG; INSIGHT START Study Group. Sereti I, et al. J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):456-462. doi: 10.1097/QAI.0000000000002052. J Acquir Immune Defic Syndr. 2019. PMID: 31241541 Free PMC article. Clinical Trial.
Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study.
Castillo-Mancilla JR, Phillips AN, Neaton JD, Neuhaus J, Sharma S, Baker JV, Collins S, Mannheimer S, Pett S, Touzeau-Römer V, Polizzotto MN, Lundgren JD, Gardner EM; INSIGHT START Study Group. Castillo-Mancilla JR, et al. J Int AIDS Soc. 2019 Jun;22(6):e25297. doi: 10.1002/jia2.25297. J Int AIDS Soc. 2019. PMID: 31250552 Free PMC article. Clinical Trial.
Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Soliman EZ, Sharma S, Arastéh K, Wohl D, Achhra A, Tambussi G, O'Connor J, Stein JH, Duprez DA, Neaton JD, Phillips A; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Soliman EZ, et al. HIV Med. 2015 Apr;16 Suppl 1(0 0):46-54. doi: 10.1111/hiv.12233. HIV Med. 2015. PMID: 25711323 Free PMC article. Clinical Trial.
36 results